Complete Transcatheter Treatment of Degenerated Bioprosthetic Mitral Regurgitation Transapical Paravalvular Leak Closure Followed by Transseptal Mitral Valve-in-Valve Replacement by Singh, Gagan D. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 8 , N O . 1 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 6 . 0 2 9IMAGES IN INTERVENTIONComplete Transcatheter Treatment
of Degenerated Bioprosthetic
Mitral Regurgitation
Transapical Paravalvular Leak Closure Followed
by Transseptal Mitral Valve-in-Valve ReplacementGagan D. Singh, MD,* Thomas W. Smith, MD,* Walter D. Boyd, MD,y Jeffrey A. Southard, MD,* Garrett B. Wong, MD,*
Femi Philip, MD,* Reginald I. Low, MD,* Jason H. Rogers, MD*A 67-year-old woman (frail, body massindex of 18, forced expiratory volume1 of0.86, Society of Thoracic Surgeons score of
12%) was referred for transcatheter correction of a
severely degenerated bioprosthetic (29-mm EdwardsFIGURE 1 MR Assessment
Transesophageal echocardiography demonstrated central MR (A) from l
preserved left ventricular systolic function. MR ¼ mitral regurgitation.
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echocardiography (TEE) conﬁrmed severe bio-
prosthesis degeneration (Figure 1). A hybrid approach
was used whereby paravalvular leak (PVL) waseaﬂet degeneration and moderate paravalvular leak (A and B) with
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FIGURE 2 Hybrid Approach
After a mini thoracotomy is performed, an 8-F side arm sheath was inserted via transapical (TA) approach and across the paravalvular leak
(PVL). (A, B) Two Amplatzer Vascular Plug II (St. Jude Medical, St. Paul, Minnesota) were delivered simultaneously from the apex for correction
of the PVL. After transseptal access, a 0.035-inch glidewire from the transseptal sheath was snared with a 35-mm Amplatz Gooseneck
Microsnare (ev3 Endovascular Inc., Plymouth, Minnesota) via the TA sheath. The glidewire was externalized, and an atrioventricular rail was
created. Balloon dilation (12 mm) of the interatrial septum was performed, allowing delivery of a 29-mm SAPIEN XT valve (Edwards Life-
sciences) mounted for antegrade implantation (similar to transapical transcatheter aortic valve replacement) on a NovaFlex catheter (Edwards
Lifesciences). This valve size was selected based on manufacturer-reported internal dimensions and CTA sizing. (C, D) Under rapid ventricular
pacing (180 beats/min), the SAPIEN XT valve was aligned coaxially and deployed using slow balloon inﬂation. CTA ¼ computed tomography
angiography.
Singh et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 4 , 2 0 1 5
Complete Transcatheter Treatment of Degenerated Bioprosthetic Mitral Regurgitation D E C E M B E R 2 1 , 2 0 1 5 : e 2 2 9 – 3 1
e230
FIGURE 3 Final Result
(A, B) Pre– and post–transesophageal echocardiography (TEE) demonstrates correction of both central mitral regurgitation and paravalvular
leak. TEE also demonstrates a signiﬁcant iatrogenic atrial septal defect (C) treated with a 30-mm Amplatzer Septal Occluder (St. Jude Medical)
(D). AVP ¼ Amplatzer Vascular Plug.
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valve-in-valve replacement (Figure 2). TEE conﬁrmed
complete correction of degenerated bioprosthetic
mitral regurgitation (MR) (Figure 3). The patient was
discharged with complete resolution of symptoms
on follow-up.
The transapical (TA) route remains the most com-
mon for transcatheter mitral valve-in-valve replace-
ment (1). However, patients with poor pulmonary
reserve and thin body framesmay be at prohibitive risk
and may not tolerate the 24-F Ascendra sheath
(Edwards Lifesciences) required for valve delivery.Herein we report a case of complete MR reduction by
using a hybrid approach whereby the PVL is corrected
ﬁrst via the TA route. Additionally, the use of the
hybrid approach allows the operator to create a coaxial
atrioventricular rail and allows for optimal alignment
of the valve-in-valve.
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